GlassScriptPhysician profile
Tracy Little
NPI 1770880171
$7,849.61
in general payments reported to CMS, 2019-2025
26 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,870 · 2022: $1,671 · 2023: $564 · 2024: $1,646 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494 · Travel and Lodging: $794 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.57 |
| Travel and Lodging | $793.86 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,109.68 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $1,480.26 | 2021-2025 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $845.99 | 2021-2025 | Synjardy, Tradjenta, Jardiance |
| Astrazeneca Pharmaceuticals LP | $658.45 | 2021-2023 | Farxiga |
| Lilly USA, LLC | $576.60 | 2021-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $402.98 | 2021-2022 | |
| Dexcom, INC. | $352.25 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $273.18 | 2021-2024 | |
| Abbott Laboratories | $247.16 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $147.64 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $120.08 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Kowa Pharmaceuticals America, INC. | $82.48 | 2021-2022 | |
| Corcept Therapeutics | $64.07 | 2021-2025 | Korlym |
| Insulet Corporation | $54.17 | 2021-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $50.64 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.80 | 2023-2024 | Repatha |
| Sequel Med Tech, LLC | $48.25 | 2025 | Twiist |
| Cequr Corporation | $46.57 | 2024-2025 | Cequr Simplicity |
| Boston Scientific Corporation | $46.55 | 2024-2025 | Watchman Flx |
| Rgh Enterprises LLC | $45.71 | 2025 | |
| Antares Pharma, INC. | $39.47 | 2025 | Xyosted |
| Glaxosmithkline, LLC. | $25.95 | 2025 | Arexvy, Shingrix |
| Becton, Dickinson and Company | $24.10 | 2021 | |
| Ibsa Pharma INC. | $20.79 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.88 | 2025 | Amvuttra |
| Nevro Corp. | $17.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Little listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.